Neogenomics Receives New Coverage from Analysts at Roth Capital (NEO)
Equities research analysts at Roth Capital initiated coverage on shares of Neogenomics (NYSE:NEO) in a research note issued to investors on Monday, AnalystRatings.Net reports. The firm set a “buy” rating and a $6.00 price target on the stock. Roth Capital’s price target would suggest a potential upside of 81.27% from the company’s current price.
Separately, analysts at Stephens initiated coverage on shares of Neogenomics in a research note on Friday, February 14th. They set an “overweight” rating and a $6.00 price target on the stock. Five research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $6.25.
Shares of Neogenomics (NYSE:NEO) traded up 1.53% during mid-day trading on Monday, hitting $3.31. The stock had a trading volume of 227,231 shares. Neogenomics has a 52-week low of $2.05 and a 52-week high of $4.69. The stock has a 50-day moving average of $3.32 and a 200-day moving average of $3.61. The company has a market cap of $163.1 million and a price-to-earnings ratio of 79.51.
Neogenomics (NYSE:NEO) last released its earnings data on Wednesday, February 19th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.02. The company had revenue of $18.30 million for the quarter, compared to the consensus estimate of $17.80 million. Analysts expect that Neogenomics will post $0.03 EPS for the current fiscal year.
NeoGenomics, Inc (NYSE:NEO) operates a network of cancer-focused testing laboratories.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.